{"id":1030501,"date":"2011-02-16T18:13:14","date_gmt":"2011-02-16T18:13:14","guid":{"rendered":"http:\/\/www.immortalitymedicine.tv\/clinical-outcomes-in-relation-to-the-daily-dose-of-recombinant-follicle-stimulating-hormone-for-ovarian-stimulation-in-in-vitro-fertilization-in-presumed-normal-responders-younger-than-39-years-a-met\/"},"modified":"2024-08-17T14:58:37","modified_gmt":"2024-08-17T18:58:37","slug":"clinical-outcomes-in-relation-to-the-daily-dose-of-recombinant-follicle-stimulating-hormone-for-ovarian-stimulation-in-in-vitro-fertilization-in-presumed-normal-responders-younger-than-39-years-a-met","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/human-reproduction\/clinical-outcomes-in-relation-to-the-daily-dose-of-recombinant-follicle-stimulating-hormone-for-ovarian-stimulation-in-in-vitro-fertilization-in-presumed-normal-responders-younger-than-39-years-a-met.php","title":{"rendered":"Clinical outcomes in relation to the daily dose of recombinant follicle-stimulating hormone for ovarian stimulation in in vitro fertilization in presumed normal responders younger than 39 years: a meta-analysis"},"content":{"rendered":"<p>BACKGROUND<\/p>\n<p>The optimal ovarian stimulation dose to obtain the best balance between the probability of pregnancy and the risk of complications, while maximizing cost-effectiveness of <I>in vitro<\/I> fertilization (IVF) treatment, is yet to be established.<\/p>\n<p>METHODS<\/p>\n<p>A systematic search of the electronic databases PubMed, EMBASE and Cochrane library, from 1984 until October 2009 for randomized controlled trials comparing different doses of recombinant FSH in IVF, was performed.<\/p>\n<p>RESULTS<\/p>\n<p>Ten studies (totaling 1952 IVF cycles) were included in the present meta-analysis, comprising patients younger than 39 years with regular menstrual cycle, normal basal FSH levels and two normal ovaries. Comparison was made between studies using a daily dose of 100 versus 200 IU recFSH, and between 150 versus 200 IU recFSH or higher. Although oocyte yield was greater in the &gt;200 IU\/day dose group, pregnancy rates were similar compared with lower dose groups. The risk of insufficient response to ovarian stimulation was greatest in the 100 IU\/day dose group. The risk of developing ovarian hyperstimulation syndrome was greater in the &gt;200 IU\/day dose group. The number of embryos available for cryopreservation was lowest in the 100 IU\/day group, but similar comparing the 150 IU\/day and the &gt;200 IU\/day dose groups.<\/p>\n<p>CONCLUSIONS<\/p>\n<p>This meta-analysis suggests that the optimal daily recFSH stimulation dose is 150 IU\/day in presumed normal responders younger than 39 years undergoing IVF. Compared with higher doses, this dose is associated with a slightly lower oocyte yield, but similar pregnancy and embryo cryopreservation rates. Furthermore, the wide spread adherence to this optimal dose will allow for a considerable reduction in IVF costs and complications.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>BACKGROUND The optimal ovarian stimulation dose to obtain the best balance between the probability of pregnancy and the risk of complications, while maximizing cost-effectiveness of in vitro fertilization (IVF) treatment, is yet to be established. METHODS A systematic search of &hellip; <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/human-reproduction\/clinical-outcomes-in-relation-to-the-daily-dose-of-recombinant-follicle-stimulating-hormone-for-ovarian-stimulation-in-in-vitro-fertilization-in-presumed-normal-responders-younger-than-39-years-a-met.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246857],"tags":[],"class_list":["post-1030501","post","type-post","status-publish","format-standard","hentry","category-human-reproduction"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1030501"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1030501"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1030501\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1030501"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1030501"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1030501"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}